AI-designed rentosertib slowed six protein-based aging clocks in a small trial, a post says

Rentosertib, an AI-designed anti-fibrotic drug still in development, showed slowing across all six proteomic, or protein-based, aging clocks in a small trial, according to a post sharing a Nature Biotechnology paper. The post calls it the first drug in development to show slowing of proteomic aging clocks. Nature Biotechnology describes the work as a phase 2a trial using six such clocks to assess anti-aging effects.